1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trials Site Management Organizations Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trials Site Management Organizations Market, by Clinical Trial Services
8.1.1 Site Management
8.1.1.1. Market Revenue and Forecast
8.1.2. Project Management
8.1.2.1. Market Revenue and Forecast
8.1.3. Regulatory
8.1.3.1. Market Revenue and Forecast
8.1.4. Onsite monitoring
8.1.4.1. Market Revenue and Forecast
9.1. Clinical Trials Site Management Organizations Market, by Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. Clinical Trials Site Management Organizations Market, by Therapeutic Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiology
10.1.2.1. Market Revenue and Forecast
10.1.3. CNS
10.1.3.1. Market Revenue and Forecast
10.1.4. Pain management
10.1.4.1. Market Revenue and Forecast
10.1.5. Endocrine
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Clinical Trial Services
11.1.2. Market Revenue and Forecast, by Phase
11.1.3. Market Revenue and Forecast, by Therapeutic Area
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.1.4.2. Market Revenue and Forecast, by Phase
11.1.4.3. Market Revenue and Forecast, by Therapeutic Area
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.1.5.2. Market Revenue and Forecast, by Phase
11.1.5.3. Market Revenue and Forecast, by Therapeutic Area
11.2. Europe
11.2.1. Market Revenue and Forecast, by Clinical Trial Services
11.2.2. Market Revenue and Forecast, by Phase
11.2.3. Market Revenue and Forecast, by Therapeutic Area
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.2.4.2. Market Revenue and Forecast, by Phase
11.2.4.3. Market Revenue and Forecast, by Therapeutic Area
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.2.5.2. Market Revenue and Forecast, by Phase
11.2.5.3. Market Revenue and Forecast, by Therapeutic Area
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Clinical Trial Services
11.2.6.2. Market Revenue and Forecast, by Phase
11.2.6.3. Market Revenue and Forecast, by Therapeutic Area
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Clinical Trial Services
11.2.7.2. Market Revenue and Forecast, by Phase
11.2.7.3. Market Revenue and Forecast, by Therapeutic Area
11.3. APAC
11.3.1. Market Revenue and Forecast, by Clinical Trial Services
11.3.2. Market Revenue and Forecast, by Phase
11.3.3. Market Revenue and Forecast, by Therapeutic Area
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.3.4.2. Market Revenue and Forecast, by Phase
11.3.4.3. Market Revenue and Forecast, by Therapeutic Area
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.3.5.2. Market Revenue and Forecast, by Phase
11.3.5.3. Market Revenue and Forecast, by Therapeutic Area
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Clinical Trial Services
11.3.6.2. Market Revenue and Forecast, by Phase
11.3.6.3. Market Revenue and Forecast, by Therapeutic Area
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Clinical Trial Services
11.3.7.2. Market Revenue and Forecast, by Phase
11.3.7.3. Market Revenue and Forecast, by Therapeutic Area
11.4. MEA
11.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.4.2. Market Revenue and Forecast, by Phase
11.4.3. Market Revenue and Forecast, by Therapeutic Area
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.4.4.2. Market Revenue and Forecast, by Phase
11.4.4.3. Market Revenue and Forecast, by Therapeutic Area
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.4.5.2. Market Revenue and Forecast, by Phase
11.4.5.3. Market Revenue and Forecast, by Therapeutic Area
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Clinical Trial Services
11.4.6.2. Market Revenue and Forecast, by Phase
11.4.6.3. Market Revenue and Forecast, by Therapeutic Area
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Clinical Trial Services
11.4.7.2. Market Revenue and Forecast, by Phase
11.4.7.3. Market Revenue and Forecast, by Therapeutic Area
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.5.2. Market Revenue and Forecast, by Phase
11.5.3. Market Revenue and Forecast, by Therapeutic Area
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Clinical Trial Services
11.5.4.2. Market Revenue and Forecast, by Phase
11.5.4.3. Market Revenue and Forecast, by Therapeutic Area
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Clinical Trial Services
11.5.5.2. Market Revenue and Forecast, by Phase
11.5.5.3. Market Revenue and Forecast, by Therapeutic Area
12.1. Clinedge
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. WCG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. ClinChoice
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Access Clinical Research
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. FOMAT Medical Research INC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. SGS
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. KV Clinical
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SMO-Pharmina
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Xylem Clinical Research
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Aurum Clinical Research
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
